摘要
目的:观察恩度联合化疗的胃癌患者外周血中CD105、CD4^+ CD25^+ Foxp3^+ Treg的变化。方法:59例胃癌患者随机分为观察组30例(恩度联合化疗组),对照组29例(单纯化疗组),ELISA方法检测血清中CD105,FACS检测外周血CD4^+ CD25^+ Foxp3^+ Treg。结果:观察组临床有效率为80.00%(24/30),明显高于对照组的51.72%(15/29)(P<0.05)。治疗后两组患者外周血CD105、CD4^+ CD25^+ Foxp3^+ Treg水平较治疗前均显著降低(P<0.05),与对照组治疗后相比,观察组外周血CD105、CD4^+ CD25^+ Foxp3^+ Treg水平降低更显著(P<0.05)。结论:恩度联合化疗治疗胃癌疗效好,CD105、CD4^+ CD25^+ Foxp3^+ Treg有可能作为预测疗效的新指标。
Objective：To observe the change of CD105 and CD4^＋CD25^＋Foxp3^＋Treg in patients with gastric cancer treated by endostar combined with chemotherapy.Methods：59 patients with gastric cancer were randomly divided into two groups（30 patients of the test group and 29 patients of the control group）.ELISA detects the level of soluble serum CD105,FACS detects the positive rate of peripheral blood CD4^＋CD25^＋Foxp3^＋Treg.Results：The response rate of the test group was 80.00%（24/30）,and was 51.72%（15/29）of the control group（P〈0.05）.CD105 and CD4^＋CD25^＋Foxp3^＋Treg level were lower after treatment than that of before treatment in both of the groups（P〈0.05）,while the level in the test group was lower than that of the control group after treatment（P〈0.05）.Conclusion：Endostar combined with chemotherapy is effective in the treatment of gastric cancer.The level of CD105 and CD4^＋CD25^＋Foxp3^＋Treg can be used as new predictors of chemotherapeutic efficacy.
作者
帖晓静
屈福莲
申凤乾
张红蕊
刘培杰
徐志巧
TIE Xiaojing QU Fulian SHEN Fengqian et al(Department of Oncology , the Central Hospital of Kai feng , He＇ nan Province 47500)
出处
《医学理论与实践》
2017年第13期1886-1888,共3页
The Journal of Medical Theory and Practice
基金
开封市科技发展计划项目(1403054)
